Prevalence of COVID‐19 related hospitalizations and mortality in adults aged ≥40 years with haemophilia: A survey from Europe

Hermans, Cédric; Astermark, Jan; Carvalho, Manuela; Dolan, G.; d’Oiron, Roseline; Fontana, Pierre; Holme, Pål André; Livnat, Tami; Klamroth, Robert; Mancuso, Maria Elisa; Marquardt, Natascha; Núñez, Ramiro; Κατσαρού, Όλγα; Pabinger, Ingrid; Quintavalle, Gabriele; Rodgers, Ryan; Valk, Paul van der; Windyga, Jerzy; Jiménez‐Yuste, Víctor; Zupan, Irena Preložnik

doi:10.1111/hae.14761

Cited by 2 publications

(15 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hermans et al conducted a study on over 20 hemophilia treatment centers and found four deaths (0.1%) among 4,050 patients with hemophilia during the COVID-19 pandemic. 19 Similarly, we did not find any deaths among our cohort of approximately 12,000 patients with CBDs in Iran. 29 In comparison, the World Health Organization reported a mortality rate of 7% across all age groups in the general population during the initial phase of the pandemic before widespread vaccination was available.…”

Section: Discussionsupporting

confidence: 45%

“…The exact number of CBD patients with COVID-19 was not reported in four studies ( n = 251, 32.5%). 8 15 19 21…”

Section: Resultsmentioning

confidence: 99%

“…Of 12 case series studies, mortality information was available in 11 studies (91.6%), 7 8 9 10 11 12 13 14 15 16 17 19 20 21 among which, 5 studies did not observe any death among their patients, 7 8 12 20 21 while others reported deaths among their study population. 13 14 15 16 17 19…”

Section: Resultsmentioning

confidence: 99%

“…Information about the comorbidities of the remaining patient was not available. 19 Among the deceased patients, one was a 9-year-old with severe hemophilia A and CNS bleeding, 16 one was a 76-year-old with mild hemophilia A, 17 one patient was a 10-year-old with a history of intracerebral hemorrhage, 15 one was over 40 years old and had hemophilia B, 19 two patients aged 54 and 60 years had severe hemophilia A, and one patient was 70 years old and had mild hemophilia A ( Table 5 ). 19…”

Section: Resultsmentioning

confidence: 99%

“…7 12 In addition to our two studies, 10 other studies conducted in different parts of the world reported on approximately 700 patients with CBDs affected by COVID-19, providing us with a clearer picture of this relationship. 8 13 14 15 16 17 18 19 20 21…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

Congenital Bleeding Disorders and COVID-19—A Systematic Literature Review

Dorgalaleh,

Safdari,

Tabibian

et al. 2023

Semin Thromb Hemost

View full text Add to dashboard Cite

Hypercoagulability is a prominent feature of coronavirus disease 2019 (COVID-19) and can lead to fatal consequences. Although the impact of COVID-19 on several disorders is well-established, its effect on congenital bleeding disorders (CBDs) is not well-documented. To address this ambiguity, a systematic review was conducted on the available studies to determine the impact of COVID-19 and vaccination aimed to prevent COVID-19 on patients with CBDs. We performed a systematic literature review using relevant keywords and followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) protocol. We conducted our search on the PubMed, Scopus, and Web of Science databases until July 2023. Out of 31 included studies, 12 case series covering 770 patients with CBD and COVID-19 were further analyzed. The majority of the patients had hemophilia A (n = 352, ∼46%) or hemophilia B (n = 74, ∼10%), while the remaining patients had von Willebrand disease (n = 43, 5.6%) or rare bleeding disorders (n = 27, 3.5%). A total of 25 deaths (3.2%) and 22 intensive care unit admissions (2.8%) were recorded. Bleeding complications were reported in the majority of the 12 case series (n = 7, 58.3%) and in most of the case reports (n = 8, ∼57%), while thrombotic complications were only reported in two studies (16.6%). The mortality rate ranged from 0% in five studies (41.6%) to 5.7% and the rate of hospitalization ranged from 0 to 40%. Bleeding complications were reported in a range of 0 to 81%, while the thrombotic complication rate in one study was 6.9%. The mortality rate varied from 0 to 5.7%, and the hospitalization rate ranged from 0 to 40%. Bleeding complications were reported in a range of 0 to 81%, while the rate of thrombotic complications in one study was 6.9%. Vaccination was reported in five case series, which included 821 patients with CBDs with the majority having hemophilia A (n = 479; 67.2%) and hemophilia B (n = 85; ∼12%). The most frequently reported side effects were myalgia (6.5%), flu-like symptoms (4.8%), fever (4.7%), and headache (4%). COVID-19 in patients with CBDs appears to provoke thrombotic complications and bleeding events more frequently, as well as a higher rate of hospitalization, which may be partially due to the increased risk of bleeding events. Although it seems that patients with CBD have lower mortality rates, further studies are necessary to fully understand this, especially considering comorbidities and low number of available studies.

show abstract

Section: Discussionsupporting

confidence: 45%

“…The exact number of CBD patients with COVID-19 was not reported in four studies ( n = 251, 32.5%). 8 15 19 21…”

Section: Resultsmentioning

confidence: 99%